TrophAmine Articles
FDA approves new premixed formulation of Astellas' Vaprisol
27 October 2008
Cytochroma initiates Ph II trial of CTA018
27 October 2008
Stock Commentary - New York week to Oct 20, 2008
27 October 2008
Abraxane gains marketing OK in Australia
27 October 2008
Gilead up almost 30% on HIV franchise
27 October 2008
RXi licenses oral RNAi tech from US university
20 October 2008
FDA approval for new Risperdal injection site
20 October 2008
Japan stock market week to Oct 6, 2008
13 October 2008
Genasense Ph III trial progressing on target
13 October 2008
J&J launches Doribax in UK
6 October 2008
FDA and Indevus agree over Nebido NDA
6 October 2008
Lilly gets third appro for Alimta
6 October 2008
Opexa MS drug fails to meet endpoints
29 September 2008
Teva presents results from the PreCISe trial
29 September 2008
Canakinumab improves SJIA symptoms 50%
29 September 2008
Novavax' VLP flu vaccine enters Ph II trial
29 September 2008
NT reports worsened loss in full-year 2008
29 September 2008
Genta will complete AGENDA enrollment
22 September 2008
China hep C market to grow to $150M in 2012
15 September 2008
AstraZeneca's Zomig nasal spray good for cluster headache
15 September 2008
NovoMix 30 leads to 2.4% HbA1c drop in insulin-naive patients.
15 September 2008
Lantus shows benefits over determir and NPH
15 September 2008
Byetta: better post-meal glucose reduction than Januvia
15 September 2008
FDA grants Akorn's IC-Green sNDA
15 September 2008
Arcalyst reduces gout flares 81% in Ph II trial
15 September 2008
Strong maintenance data for olanzapine LAI
15 September 2008
FDA delay for J&J's Doribax
1 September 2008
Eisai/Helsinn's Aloxi capsules approved in USA
1 September 2008
Pharmalink reports positive Ph III data with PPS injection
1 September 2008
UPDATE: FDA considering strong warning on Byetta; potential fall-out for all GLP-1s
1 September 2008
Delay for J&J's schizophrenia injection
1 September 2008
APP Puerto Rico heparin facility cleared by FDA
1 September 2008
FDA labeling rule upsets trial lawyers
1 September 2008
NEJM editors side against Wyeth
1 September 2008
Vical's Vaxfectin to be studied for HIV DNA vacc
1 September 2008
US regulators ask for more clinical studies of Kynapid
18 August 2008
Law suits stall awaiting FDA pre-emption verdict
18 August 2008
Celgene profits double on rocketing sales
11 August 2008
Merck Serono to grow Japanese business
4 August 2008
US FDA rejects Eisai's fospropofol
4 August 2008
Duska files Ph III ATPace protocol with FDA
4 August 2008
Amylin's 2nd-qtr 2008 loss widens to $64.8M
4 August 2008
Genzyme's 2nd qtr profit hit by license cost
4 August 2008
Gilead profits up 9% on HIV franchise sales
28 July 2008
Teva's laquinimod enters Ph III study
21 July 2008
FDA accepts Genta's complete response on Genasense
21 July 2008
Japan stock market week to July 14, 2008
21 July 2008
First commercial launch from Akorn Strides
21 July 2008
China Sky One has 11 generics in pipeline
21 July 2008
Aloxi launched in USA for PONV
14 July 2008
Japan stock market week to July 7, 2008
14 July 2008
Wyeth/Progenics' Reslitor approved in EU
14 July 2008
Cubist to promote AstraZeneca's Merrem in USA
7 July 2008
Bioniche acquires Baxter's Enlon line
7 July 2008
Hana Bio gets US orphan status for Marquibo
7 July 2008
Japan stock market week to June 30, 2008
7 July 2008
Thrombogenics reports on vitrectomy study
7 July 2008
Millennium/J&J's FDA approval for Velcade
30 June 2008
Humira launched in Japan for treatment of RA
30 June 2008
Generex Oral-lyn non-inferior to insulin analogs
30 June 2008
Lexiscan launch earns CV $10M milestone
30 June 2008
Genta updates of Genasense Ph III progress
30 June 2008
Algeta start enrollment in Ph III Alpharadin trial
30 June 2008
FDA clears Allergan's Trivaris
23 June 2008
J&J psoriasis candidate may cause cancer; FDA
23 June 2008
RA golimumab patients see DAS28 remissions
23 June 2008
Lilly pays $35M for TP's osteoperosis patch
23 June 2008
Levemir comparable to glargine in control and DACON
16 June 2008
Amylin/Lilly's Byetta achieves glycemic control
16 June 2008
66% of Lantus patients meet ADA's 7% target
16 June 2008
Riken identifies potential AD drug
16 June 2008
Roche's reclast gets expanded US label
16 June 2008
Ph III data for Wyeth's Relistor injection
9 June 2008
Novartis buys Protez for $100M
9 June 2008
J&J's Doribax gets CHMP OK for NP
9 June 2008
Alimta boosts survival in certain NSCLC types
9 June 2008
Akorn-Strides' rifampin cleared by FDA
2 June 2008
Japan stock market week to May 26, 2008
2 June 2008
MS drug pipeline update from Bayer Schering
26 May 2008
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
